Time filter

Source Type

San Diego, CA, United States

Dasanu C.A.,Saint Francis Medical Center College of Nursing | Ichim T.E.,Medistem Inc | Alexandrescu D.T.,Regen BioPharma Inc.
Journal of Oncology Pharmacy Practice | Year: 2013

Transverse leukonychia (Leukonychia striata or Muehrcke's lines) has been described with the use of several drugs in oncology, mainly chemotherapeutic agents. This condition is thought to represent an abnormality of the vascular nail bed. As the diagnosis is clinical and the condition is self-limited, referral to other specialists is usually not required. We report the first case of transverse leukonychia related to the use of transretinoic acid for acute promyelocytic leukemia. Physician awareness of transverse leukonychia is important in order to reassure the patients and avoid unnecessary (and often not inexpensive) diagnostic work-up. © 2013 The Author(s).

Maslin B.,Yale University | Alexandrescu D.T.,Regen BioPharma Inc. | Ichim T.E.,Medistem Inc | Dasanu C.A.,St Francis Hospital and Medical Center
Journal of Oncology Pharmacy Practice | Year: 2014

Individuals with malignant melanoma present a variety of immune abnormalities including but not limited to cellular immune dysfunction, antigen presentation deficits, and cytokine production defects. Therefore, enhancing the immune system potential represents an appealing avenue for melanoma therapy. The authors review the immune therapies currently in clinical use as well as the most promising immunotherapy candidates. Ipilimumab, a monoclonal antibody against the CTLA-4, was approved for the therapy of advanced melanoma in 2011. In addition, sizeable anti-melanoma activity has recently been shown with the use of other agents including anti-PD-1/anti-PD-1 ligand antibodies. Consequently, these experimental immunotherapy agents may soon become important items in the anti-melanoma armamentarium. © The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Regen BioPharma Inc. | Date: 2016-04-25

Pharmaceutical products for the prevention and treatment of cancer.

Regen BioPharma Inc | Date: 2016-02-05

Pharmaceutical products for the prevention and treatment of cancer.

Treatment of cancer is disclosed through administration of proteins or specific peptides in vivo, in a matter eliciting monocyte or dendritic cell migration in order to allow uptake of said administrated proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor associated blood vessels.

Discover hidden collaborations